{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-112750","form_type":"8-K","ticker":"KNSA","cik":"0001730430","company_name":"Kiniksa Pharmaceuticals International, plc","filed_at":"2023-10-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.216378+00:00","generated_at":"2026-06-09T04:48:27.076390+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Kiniksa Q3 ARCALYST revenue $64.8M (+94% YoY); tracking to high end of FY guidance","bullets":["ARCALYST net product revenue $64.8M, ~94% YoY growth; total revenue $67.0M (incl. $2.2M license).","Net loss $13.9M vs net income $224.1M in Q3 2022 (prior year included $65.7M license revenue).","Cash $201.1M, no debt; expected to fund operations into at least 2027.","KPL-404 Phase 2 RA data from Cohorts 1-3 expected Q1 2024; Cohort 4 data expected Q2 2024.","FY2023 ARCALYST revenue guidance $220-230M, tracking to high end."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-112750","json":"https://secwatch.observer/filing/0001104659-23-112750.json","markdown":"https://secwatch.observer/filing/0001104659-23-112750.md","text":"https://secwatch.observer/filing/0001104659-23-112750.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1730430/000110465923112750/0001104659-23-112750-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1730430/000110465923112750/tm2329311-1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T04:48:27.076390+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"32808ee13a4a5d0035d39398223fe7e0a0328c77","claim":"Kiniksa Pharmaceuticals International, plc reported financial results for third quarter 2023.","evidence_excerpt":"On October 31, 2023, Kiniksa Pharmaceuticals, Ltd. issued a press release announcing financial results for the quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1730430/000110465923112750/0001104659-23-112750-index.htm","confidence":0.4,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}